MRFF Fellowships
Prof John Zalcberg, Professor of Cancer Research, Department of Epidemiology and Preventive Medicine, Monash University A national cancer outcome strategy ($487,893.00) |
A/Prof Andrew Wei, Head of Leukaemia Research, Australian Centre for Blood Diseases, Monash University and Alfred Health Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia ($412,419) |
A/Prof Jake Shortt, Head of Haematology Research, School of Clinical Sciences, Monash University and Monash Health Next generation targeting of DNA methylation in poor risk lymphoid cancer ($ 218,518) |
Dr Karen Alt, Senior Researcher, Australian Centre for Blood Diseases, Monash University Novel targeted oncotheranostic nanoparticles for personalised therapy and real-time monitoring ($431,000) |
MRFF Clinical Trials
Prof Andrew Spencer, Head of the Malignant Haematology & Stem Cell Transplantation Service, Alfred Health Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma – the FRAIL-M study ($1,682,835) |
Prof Andrew Perkins, Head of the Blood Cancer Genomics Lab, Australian Centre for Blood Diseases, Monash University Improving survival in myelofibrosis ($1,733,327) |
Prof Erica Wood, Head of the Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University The DIAAMOND study: Diagnosis of aplastic anaemia, management, and outcomes utilising a national dataset ($ 1,750,726) |
A/Prof Andrew Wei, Head of Leukaemia Research, Australian Centre for Blood Diseases, Monash University and Alfred Health A registry-linked national platform trial to improve precision-based outcomes using novel therapies in acute myeloid leukemia (AML) ($1,507,785) |